Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
16.4 USD | +2.92% | -6.51% | -2.39% |
06-20 | Avrobio Closes Merger With Tectonic Therapeutic | MT |
06-20 | Tectonic Therapeutic, Inc. announced that it has received $96.599856 million in funding from Tas Partners, LLC | CI |
Valuation
Fiscal Period: December | 2024 | 2025 | 2026 |
---|---|---|---|
Capitalization 1 | 234.7 | - | - |
Enterprise Value (EV) 1 | 234.7 | 234.7 | 234.7 |
P/E ratio | -2.29 x | -3.41 x | -2.97 x |
Yield | - | - | - |
Capitalization / Revenue | - | - | - |
EV / Revenue | - | - | - |
EV / EBITDA | - | - | - |
EV / FCF | -4.12 x | -3.5 x | -2.73 x |
FCF Yield | -24.3% | -28.5% | -36.6% |
Price to Book | - | - | - |
Nbr of stocks (in thousands) | 14,734 | - | - |
Reference price 2 | 15.93 | 15.93 | 15.93 |
Announcement Date | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Net sales 1 | - | - | - | - |
EBITDA | - | - | - | - |
EBIT 1 | - | -59.83 | -75.02 | -92.56 |
Operating Margin | - | - | - | - |
Earnings before Tax (EBT) 1 | -42.82 | -60.56 | -75.02 | -92.56 |
Net income 1 | -42.82 | -60.56 | -75.02 | -92.56 |
Net margin | - | - | - | - |
EPS 2 | - | -6.960 | -4.665 | -5.365 |
Free Cash Flow 1 | - | -57 | -67 | -86 |
FCF margin | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - |
Dividend per Share | - | - | - | - |
Announcement Date | 24-03-26 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|
Net sales 1 | - | - | - | - |
EBITDA | - | - | - | - |
EBIT 1 | -14.36 | -15.67 | -17.32 | -17.77 |
Operating Margin | - | - | - | - |
Earnings before Tax (EBT) 1 | -14.23 | -15.54 | -17.18 | -17.77 |
Net income 1 | -14.23 | -15.54 | -17.18 | -17.77 |
Net margin | - | - | - | - |
EPS 2 | -1.955 | -1.030 | -1.105 | -1.130 |
Dividend per Share | - | - | - | - |
Announcement Date | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Net Debt | - | - | - | - |
Net Cash position | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - |
Free Cash Flow 1 | - | -57 | -67 | -86 |
ROE (net income / shareholders' equity) | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - |
Assets 1 | - | - | - | - |
Book Value Per Share | - | - | - | - |
Cash Flow per Share | - | - | - | - |
Capex 1 | - | 2 | 3 | 4 |
Capex / Sales | - | - | - | - |
Announcement Date | 24-03-26 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.39% | 235M | |
+16.41% | 122B | |
+19.30% | 115B | |
+21.22% | 26.64B | |
-23.74% | 19.91B | |
-17.47% | 16.32B | |
-45.95% | 15.52B | |
-18.39% | 15.49B | |
+64.04% | 14.83B | |
+2.23% | 13.67B |
- Stock Market
- Equities
- AVRO Stock
- Financials Tectonic Therapeutic, Inc.